FOLD Q1 2023 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+9.6% YoY

Gross Profit

$79M92.0% margin

Operating Income

-$38M-43.6% margin

Net Income

-$53M-61.4% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-2.1%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$20M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$701M

Total Liabilities

$598M

Stockholders' Equity

$103M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$79M	+9.6%
Gross Profit	$79M	$71M	+11.5%
Operating Income	-$38M	-$75M	+50.0%
Net Income	-$53M	-$85M	+37.9%

Geographic Segments

Non-US

$57M67%

UNITED STATES

$29M33%